# An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

> **NCT01403038** · PHASE1 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 216 (actual)

## Conditions studied

- Folliculogenesis

## Interventions

- **DRUG:** Elagolix
- **DRUG:** Elagolix
- **DRUG:** Elagolix
- **DRUG:** Elagolix
- **DRUG:** Elagolix
- **DRUG:** Elagolix
- **DRUG:** elagolix

## Key facts

- **NCT ID:** NCT01403038
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-10
- **Final completion:** 2012-11
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2013-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01403038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01403038, "An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01403038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*